U.S. markets close in 5 hours 11 minutes
  • S&P 500

    3,292.01
    -98.67 (-2.91%)
     
  • Dow 30

    26,645.09
    -818.10 (-2.98%)
     
  • Nasdaq

    11,080.21
    -351.14 (-3.07%)
     
  • Russell 2000

    1,549.22
    -41.26 (-2.59%)
     
  • Crude Oil

    37.66
    -1.91 (-4.83%)
     
  • Gold

    1,876.70
    -35.20 (-1.84%)
     
  • Silver

    23.24
    -1.33 (-5.41%)
     
  • EUR/USD

    1.1730
    -0.0059 (-0.50%)
     
  • 10-Yr Bond

    0.7590
    -0.0190 (-2.44%)
     
  • GBP/USD

    1.2982
    -0.0059 (-0.45%)
     
  • USD/JPY

    104.2280
    -0.2660 (-0.25%)
     
  • BTC-USD

    13,111.60
    -598.42 (-4.36%)
     
  • CMC Crypto 200

    259.77
    -12.92 (-4.74%)
     
  • FTSE 100

    5,557.01
    -171.98 (-3.00%)
     
  • Nikkei 225

    23,418.51
    -67.29 (-0.29%)
     

Benzinga's Top Upgrades, Downgrades For August 20, 2020

Benzinga Insights
·11 mins read

Upgrades

  • For Cinemark Holdings Inc (NYSE: CNK), Benchmark upgraded the previous rating of Hold to the current rating Buy. For the second quarter, Cinemark Hldgs had an EPS of $1.27, compared to year-ago quarter EPS of $0.86. The stock has a 52-week-high of $39.81 and a 52-week-low of $5.71. At the end of the last trading period, Cinemark Hldgs closed at $11.14.

  • For OGE Energy Corp (NYSE: OGE), Guggenheim upgraded the previous rating of Neutral to the current rating Buy. OGE Energy earned $0.51 in the second quarter, compared to $0.50 in the year-ago quarter. The stock has a 52-week-high of $46.43 and a 52-week-low of $23.00. At the end of the last trading period, OGE Energy closed at $32.08.

  • According to Northland Capital Markets, the prior rating for Power Integrations Inc (NASDAQ: POWI) was changed from Underperform to Market Perform. For the second quarter, Power Integrations had an EPS of $0.66, compared to year-ago quarter EPS of $0.56. At the moment, the stock has a 52-week-high of $127.39 and a 52-week-low of $56.88. Power Integrations closed at $57.30 at the end of the last trading period.

  • According to DBS Bank, the prior rating for Sea Ltd (NYSE: SE) was changed from Sell to Buy. For the second quarter, Sea had an EPS of $0.68, compared to year-ago quarter EPS of $0.68. At the moment, the stock has a 52-week-high of $154.25 and a 52-week-low of $26.41. Sea closed at $150.58 at the end of the last trading period.

  • For Shake Shack Inc (NYSE: SHAK), Wedbush upgraded the previous rating of Neutral to the current rating Outperform. For the second quarter, Shake Shack had an EPS of $0.45, compared to year-ago quarter EPS of $0.27. The current stock performance of Shake Shack shows a 52-week-high of $105.84 and a 52-week-low of $30.01. Moreover, at the end of the last trading period, the closing price was at $53.87.

  • According to Barclays, the prior rating for Dana Inc (NYSE: DAN) was changed from Equal-Weight to Overweight. In the second quarter, Dana showed an EPS of $0.69, compared to $0.87 from the year-ago quarter. The stock has a 52-week-high of $19.21 and a 52-week-low of $4.22. At the end of the last trading period, Dana closed at $13.17.

  • For Elanco Animal Health Inc (NYSE: ELAN), Morgan Stanley upgraded the previous rating of Equal-Weight to the current rating Overweight. For the second quarter, Elanco Animal Health had an EPS of $0.09, compared to year-ago quarter EPS of $0.28. At the moment, the stock has a 52-week-high of $32.66 and a 52-week-low of $15.17. Elanco Animal Health closed at $25.80 at the end of the last trading period.

 

Downgrades

  • For Vipshop Holdings Ltd (NYSE: VIPS), JP Morgan downgraded the previous rating of Overweight to the current rating Neutral. For the second quarter, Vipshop Holdings had an EPS of $0.27, compared to year-ago quarter EPS of $0.23. The stock has a 52-week-high of $24.46 and a 52-week-low of $7.69. At the end of the last trading period, Vipshop Holdings closed at $19.26.

  • According to Raymond James, the prior rating for Ventas Inc (NYSE: VTR) was changed from Strong Buy to Outperform. Ventas earned $0.77 in the second quarter, compared to $0.97 in the year-ago quarter. At the moment, the stock has a 52-week-high of $75.40 and a 52-week-low of $13.35. Ventas closed at $40.38 at the end of the last trading period.

  • According to Benchmark, the prior rating for Regeneron Pharmaceuticals Inc (NASDAQ: REGN) was changed from Buy to Hold. For the second quarter, Regeneron Pharmaceuticals had an EPS of $7.16, compared to year-ago quarter EPS of $6.04. The current stock performance of Regeneron Pharmaceuticals shows a 52-week-high of $664.64 and a 52-week-low of $271.37. Moreover, at the end of the last trading period, the closing price was at $629.63.

  • For Biomarin Pharmaceutical Inc (NASDAQ: BMRN), RBC Capital downgraded the previous rating of Outperform to the current rating Sector Perform. Biomarin Pharmaceutical earned $0.16 in the second quarter, compared to $0.29 in the year-ago quarter. The current stock performance of Biomarin Pharmaceutical shows a 52-week-high of $131.94 and a 52-week-low of $62.88. Moreover, at the end of the last trading period, the closing price was at $76.72.

  • Wells Fargo downgraded the previous rating for Crown Castle International Corp (NYSE: CCI) from Overweight to Equal-Weight. In the second quarter, Crown Castle Intl showed an EPS of $1.45, compared to $1.41 from the year-ago quarter. The stock has a 52-week-high of $180.00 and a 52-week-low of $114.18. At the end of the last trading period, Crown Castle Intl closed at $162.69.

  • For Momenta Pharmaceuticals Inc (NASDAQ: MNTA), Stifel downgraded the previous rating of Buy to the current rating Hold. Momenta Pharmaceuticals earned $0.48 in the second quarter, compared to $1.16 in the year-ago quarter. The current stock performance of Momenta Pharmaceuticals shows a 52-week-high of $52.21 and a 52-week-low of $11.91. Moreover, at the end of the last trading period, the closing price was at $52.12.

  • For Principia Biopharma Inc (NASDAQ: PRNB), Stifel downgraded the previous rating of Buy to the current rating Hold. Principia Biopharma earned $0.31 in the second quarter, compared to $0.28 in the year-ago quarter. The stock has a 52-week-high of $100.04 and a 52-week-low of $25.35. At the end of the last trading period, Principia Biopharma closed at $99.70.

  • For Teligent Inc (NASDAQ: TLGT), Craig-Hallum downgraded the previous rating of Buy to the current rating Hold. Teligent earned $1.54 in the second quarter, compared to $0.04 in the year-ago quarter. At the moment, the stock has a 52-week-high of $5.94 and a 52-week-low of $0.19. Teligent closed at $2.01 at the end of the last trading period.

  • Credit Suisse downgraded the previous rating for Sarepta Therapeutics Inc (NASDAQ: SRPT) from Outperform to Neutral. In the second quarter, Sarepta Therapeutics showed an EPS of $1.51, compared to $0.83 from the year-ago quarter. The stock has a 52-week-high of $175.00 and a 52-week-low of $72.05. At the end of the last trading period, Sarepta Therapeutics closed at $148.66.

 

Initiations

  • Deutsche Bank initiated coverage on Check Point Software Technologies Ltd (NASDAQ: CHKP) with a Hold rating. The price target for Check Point Software is set to $128.00. Check Point Software earned $1.58 in the second quarter, compared to $1.38 in the year-ago quarter. The current stock performance of Check Point Software shows a 52-week-high of $130.65 and a 52-week-low of $80.06. Moreover, at the end of the last trading period, the closing price was at $128.08.

  • With a current rating of Outperform, Evercore ISI Group initiated coverage on 8x8 Inc (NYSE: EGHT). The price target seems to have been set at $23.00 for 8x8. 8x8 earned $0.07 in the first quarter, compared to $0.14 in the year-ago quarter. The stock has a 52-week-high of $25.25 and a 52-week-low of $10.70. At the end of the last trading period, 8x8 closed at $16.28.

  • Morgan Stanley initiated coverage on ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) with an Overweight rating. The price target for ACADIA Pharmaceuticals is set to $55.00. In the second quarter, ACADIA Pharmaceuticals showed an EPS of $0.27, compared to $0.38 from the year-ago quarter. The current stock performance of ACADIA Pharmaceuticals shows a 52-week-high of $58.72 and a 52-week-low of $23.77. Moreover, at the end of the last trading period, the closing price was at $38.91.

  • Deutsche Bank initiated coverage on Fortinet Inc (NASDAQ: FTNT) with a Hold rating. The price target for Fortinet is set to $131.00. Fortinet earned $0.82 in the second quarter, compared to $0.58 in the year-ago quarter. The current stock performance of Fortinet shows a 52-week-high of $151.95 and a 52-week-low of $70.20. Moreover, at the end of the last trading period, the closing price was at $129.51.

  • Needham initiated coverage on Vir Biotechnology Inc (NASDAQ: VIR) with a Buy rating. The price target for Vir Biotechnology is set to $62.00. Vir Biotechnology earned $0.27 in the second quarter. At the moment, the stock has a 52-week-high of $75.00 and a 52-week-low of $11.65. Vir Biotechnology closed at $50.43 at the end of the last trading period.

  • Morgan Stanley initiated coverage on Evofem Biosciences Inc (NASDAQ: EVFM) with a Equal-Weight rating. In the second quarter, Evofem Biosciences showed an EPS of $0.39, compared to $0.95 from the year-ago quarter. The stock has a 52-week-high of $7.50 and a 52-week-low of $2.73. At the end of the last trading period, Evofem Biosciences closed at $3.36.

  • With a current rating of In-Line, Evercore ISI Group initiated coverage on Five9 Inc (NASDAQ: FIVN). The price target seems to have been set at $122.00 for Five9. For the second quarter, Five9 had an EPS of $0.21, compared to year-ago quarter EPS of $0.20. The stock has a 52-week-high of $131.98 and a 52-week-low of $50.73. At the end of the last trading period, Five9 closed at $124.59.

  • Oppenheimer initiated coverage on Fulgent Genetics Inc (NASDAQ: FLGT) with an Outperform rating. The price target for Fulgent Genetics is set to $75.00. Fulgent Genetics earned $0.17 in the second quarter, compared to $0.06 in the year-ago quarter. At the moment, the stock has a 52-week-high of $47.85 and a 52-week-low of $6.70. Fulgent Genetics closed at $44.01 at the end of the last trading period.

  • Goldman Sachs initiated coverage on Flexion Therapeutics Inc (NASDAQ: FLXN) with a Neutral rating. The price target for Flexion Therapeutics is set to $15.00. Flexion Therapeutics earned $0.76 in the second quarter, compared to $0.96 in the year-ago quarter. The current stock performance of Flexion Therapeutics shows a 52-week-high of $22.98 and a 52-week-low of $5.01. Moreover, at the end of the last trading period, the closing price was at $12.65.

  • With a current rating of Overweight, Wells Fargo initiated coverage on Tandem Diabetes Care Inc (NASDAQ: TNDM). The price target seems to have been set at $120.00 for Tandem Diabetes Care. For the second quarter, Tandem Diabetes Care had an EPS of $0.45, compared to year-ago quarter EPS of $0.03. The stock has a 52-week-high of $110.80 and a 52-week-low of $43.69. At the end of the last trading period, Tandem Diabetes Care closed at $107.33.

  • Berenberg initiated coverage on Eaton Corp PLC (NYSE: ETN) with a Hold rating. The price target for Eaton Corp is set to $110.00. Eaton Corp earned $0.70 in the second quarter, compared to $1.53 in the year-ago quarter. At the moment, the stock has a 52-week-high of $105.78 and a 52-week-low of $56.41. Eaton Corp closed at $100.48 at the end of the last trading period.

  • With a current rating of Buy, Berenberg initiated coverage on Emerson Electric Co (NYSE: EMR). The price target seems to have been set at $83.00 for Emerson Electric. For the third quarter, Emerson Electric had an EPS of $0.80, compared to year-ago quarter EPS of $0.94. The current stock performance of Emerson Electric shows a 52-week-high of $78.38 and a 52-week-low of $37.75. Moreover, at the end of the last trading period, the closing price was at $68.32.

  • With a current rating of Buy, Berenberg initiated coverage on Rockwell Automation Inc (NYSE: ROK). The price target seems to have been set at $270.00 for Rockwell Automation. In the third quarter, Rockwell Automation showed an EPS of $1.27, compared to $2.40 from the year-ago quarter. At the moment, the stock has a 52-week-high of $238.49 and a 52-week-low of $115.38. Rockwell Automation closed at $228.68 at the end of the last trading period.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.